Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors

KRAS mutations drive a quarter of cancer mortality, and most are undruggable. Several inhibitors of the MAPK pathway are FDA approved but poorly tolerated at the doses needed to adequately extinguish RAS/RAF/MAPK signaling in the tumor cell. We found that oncogenic KRAS signaling induced ferrous iro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Honglin, Muir, Ryan K., Gonciarz, Ryan L., Olshen, Adam B., Yeh, Iwei, Hann, Byron C., Zhao, Ning, Wang, Yung-hua, Behr, Spencer C., Korkola, James E., Evans, Michael J., Collisson, Eric A., Renslo, Adam R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916116/
https://www.ncbi.nlm.nih.gov/pubmed/35262628
http://dx.doi.org/10.1084/jem.20210739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916116/
https://www.ncbi.nlm.nih.gov/pubmed/35262628
http://dx.doi.org/10.1084/jem.20210739

Ejemplares similares